Transcutaneous Administration of Imiquimod Promotes T and B Cell Differentiation into Effector Cells or Plasma Cells

Transcutaneous Administration of Imiquimod Promotes T and B Cell Differentiation into Effector Cells or Plasma Cells

We are interested in promoting the development of transcutaneous immunization using microneedle technology and attempting to apply an adjuvant with transcutaneous immunization to improve the efficacy and reduce the amount of antigen and number of administrations needed. In this study, we collected b...

Full description

Bibliographic Details
Main Authors: Sachiko Hirobe, Taki Yamasaki, Sayami Ito, Ying-Shu Quan, Fumio Kamiyama, Masashi Tachibana, Naoki Okada
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Pharmaceutics
Subjects:
transcutaneous immunization
microneedle
TLR7 ligand
adjuvant
imiquimod
Online Access:https://www.mdpi.com/1999-4923/14/2/385

Internet

https://www.mdpi.com/1999-4923/14/2/385

Similar Items